Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price DropGlobeNewsWire • Thursday
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • Thursday
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key MetricsZacks Investment Research • Thursday
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period ProgressBusiness Wire • Thursday
Alnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • Wednesday
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease TranscriptSeeking Alpha • Tuesday
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's DiseaseBusiness Wire • 10/23/26
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/22/26
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?The Motley Fool • 10/21/26
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial ResultsBusiness Wire • 10/15/26
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmGlobeNewsWire • 10/05/26
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationGlobeNewsWire • 10/05/26
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzGlobeNewsWire • 10/02/26
AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CMBusiness Wire • 09/29/26
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.The Motley Fool • 09/28/26